Cargando…

Wells–Dawson phosphotungstates as mushroom tyrosinase inhibitors: a speciation study

In order to elucidate the active polyoxotungstate (POT) species that inhibit fungal polyphenol oxidase (AbPPO4) in sodium citrate buffer at pH 6.8, four Wells–Dawson phosphotungstates [α/β-P(V)(2)W(VI)(18)O(62)](6−) (intact form), [α(2)-P(V)(2)W(VI)(17)O(61)](10−) (monolacunary), [P(V)(2)W(VI)(15)O(...

Descripción completa

Detalles Bibliográficos
Autores principales: Lampl, Raphael, Breibeck, Joscha, Gumerova, Nadiia I., Galanski, Mathea Sophia, Rompel, Annette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481536/
https://www.ncbi.nlm.nih.gov/pubmed/34588468
http://dx.doi.org/10.1038/s41598-021-96491-5
_version_ 1784576693728444416
author Lampl, Raphael
Breibeck, Joscha
Gumerova, Nadiia I.
Galanski, Mathea Sophia
Rompel, Annette
author_facet Lampl, Raphael
Breibeck, Joscha
Gumerova, Nadiia I.
Galanski, Mathea Sophia
Rompel, Annette
author_sort Lampl, Raphael
collection PubMed
description In order to elucidate the active polyoxotungstate (POT) species that inhibit fungal polyphenol oxidase (AbPPO4) in sodium citrate buffer at pH 6.8, four Wells–Dawson phosphotungstates [α/β-P(V)(2)W(VI)(18)O(62)](6−) (intact form), [α(2)-P(V)(2)W(VI)(17)O(61)](10−) (monolacunary), [P(V)(2)W(VI)(15)O(56)](12−) (trilacunary) and [H(2)P(V)(2)W(VI)(12)O(48)](12−) (hexalacunary) were investigated. The speciation of the POT solutions under the dopachrome assay (50 mM Na-citrate buffer, pH 6.8; L-3,4−dihydroxyphenylalanine as a substrate) conditions were determined by (183)W-NMR, (31)P-NMR spectroscopy and mass spectrometry. The intact Wells–Dawson POT [α/β-P(V)(2)W(VI)(18)O(62)](6−) shows partial (~ 69%) disintegration into the monolacunary [α(2)-P(V)(2)W(VI)(17)O(61)](10−) anion with moderate activity (K(i) = 9.7 mM). The monolacunary [α(2)-P(V)(2)W(VI)(17)O(61)](10−) retains its structural integrity and exhibits the strongest inhibition of AbPPO4 (K(i) = 6.5 mM). The trilacunary POT [P(V)(2)W(VI)(15)O(56)](12−) rearranges to the more stable monolacunary [α(2)-P(V)(2)W(VI)(17)O(61)](10−) (~ 62%) accompanied by release of free phosphates and shows the weakest inhibition (K(i) = 13.6 mM). The hexalacunary anion [H(2)P(V)(2)W(VI)(12)O(48)](12−) undergoes time-dependent hydrolysis resulting in a mixture of [H(2)P(V)(2)W(VI)(12)O(48)](12−), [P(V)(8)W(VI)(48)O(184)](40−), [P(V)(2)W(VI)(19)O(69)(H(2)O)](14−) and [α(2)-P(V)(2)W(VI)(17)O(61)](10−) which together leads to comparable inhibitory activity (K(i) = 7.5 mM) after 48 h. For the solutions of [α/β-P(V)(2)W(VI)(18)O(62)](6−), [α(2)-P(V)(2)W(VI)(17)O(61)](10−) and [P(V)(2)W(VI)(15)O(56)](12−) the inhibitory activity is correlated to the degree of their rearrangement to [α(2)-P(V)(2)W(VI)(17)O(61)](10−). The rearrangement of hexalacunary [H(2)P(V)(2)W(VI)(12)O(48)](12−) into at least four POTs with a negligible amount of monolacunary anion interferes with the correlation of activity to the degree of their rearrangement to [α(2)-P(V)(2)W(VI)(17)O(61)](10−). The good inhibitory effect of the Wells–Dawson [α(2)-P(V)(2)W(VI)(17)O(61)](10−) anion is explained by the low charge density of its protonated forms H(x)[α(2)-P(V)(2)W(VI)(17)O(61)]((10−x)−) (x = 3 or 4) at pH 6.8.
format Online
Article
Text
id pubmed-8481536
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-84815362021-10-01 Wells–Dawson phosphotungstates as mushroom tyrosinase inhibitors: a speciation study Lampl, Raphael Breibeck, Joscha Gumerova, Nadiia I. Galanski, Mathea Sophia Rompel, Annette Sci Rep Article In order to elucidate the active polyoxotungstate (POT) species that inhibit fungal polyphenol oxidase (AbPPO4) in sodium citrate buffer at pH 6.8, four Wells–Dawson phosphotungstates [α/β-P(V)(2)W(VI)(18)O(62)](6−) (intact form), [α(2)-P(V)(2)W(VI)(17)O(61)](10−) (monolacunary), [P(V)(2)W(VI)(15)O(56)](12−) (trilacunary) and [H(2)P(V)(2)W(VI)(12)O(48)](12−) (hexalacunary) were investigated. The speciation of the POT solutions under the dopachrome assay (50 mM Na-citrate buffer, pH 6.8; L-3,4−dihydroxyphenylalanine as a substrate) conditions were determined by (183)W-NMR, (31)P-NMR spectroscopy and mass spectrometry. The intact Wells–Dawson POT [α/β-P(V)(2)W(VI)(18)O(62)](6−) shows partial (~ 69%) disintegration into the monolacunary [α(2)-P(V)(2)W(VI)(17)O(61)](10−) anion with moderate activity (K(i) = 9.7 mM). The monolacunary [α(2)-P(V)(2)W(VI)(17)O(61)](10−) retains its structural integrity and exhibits the strongest inhibition of AbPPO4 (K(i) = 6.5 mM). The trilacunary POT [P(V)(2)W(VI)(15)O(56)](12−) rearranges to the more stable monolacunary [α(2)-P(V)(2)W(VI)(17)O(61)](10−) (~ 62%) accompanied by release of free phosphates and shows the weakest inhibition (K(i) = 13.6 mM). The hexalacunary anion [H(2)P(V)(2)W(VI)(12)O(48)](12−) undergoes time-dependent hydrolysis resulting in a mixture of [H(2)P(V)(2)W(VI)(12)O(48)](12−), [P(V)(8)W(VI)(48)O(184)](40−), [P(V)(2)W(VI)(19)O(69)(H(2)O)](14−) and [α(2)-P(V)(2)W(VI)(17)O(61)](10−) which together leads to comparable inhibitory activity (K(i) = 7.5 mM) after 48 h. For the solutions of [α/β-P(V)(2)W(VI)(18)O(62)](6−), [α(2)-P(V)(2)W(VI)(17)O(61)](10−) and [P(V)(2)W(VI)(15)O(56)](12−) the inhibitory activity is correlated to the degree of their rearrangement to [α(2)-P(V)(2)W(VI)(17)O(61)](10−). The rearrangement of hexalacunary [H(2)P(V)(2)W(VI)(12)O(48)](12−) into at least four POTs with a negligible amount of monolacunary anion interferes with the correlation of activity to the degree of their rearrangement to [α(2)-P(V)(2)W(VI)(17)O(61)](10−). The good inhibitory effect of the Wells–Dawson [α(2)-P(V)(2)W(VI)(17)O(61)](10−) anion is explained by the low charge density of its protonated forms H(x)[α(2)-P(V)(2)W(VI)(17)O(61)]((10−x)−) (x = 3 or 4) at pH 6.8. Nature Publishing Group UK 2021-09-29 /pmc/articles/PMC8481536/ /pubmed/34588468 http://dx.doi.org/10.1038/s41598-021-96491-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Lampl, Raphael
Breibeck, Joscha
Gumerova, Nadiia I.
Galanski, Mathea Sophia
Rompel, Annette
Wells–Dawson phosphotungstates as mushroom tyrosinase inhibitors: a speciation study
title Wells–Dawson phosphotungstates as mushroom tyrosinase inhibitors: a speciation study
title_full Wells–Dawson phosphotungstates as mushroom tyrosinase inhibitors: a speciation study
title_fullStr Wells–Dawson phosphotungstates as mushroom tyrosinase inhibitors: a speciation study
title_full_unstemmed Wells–Dawson phosphotungstates as mushroom tyrosinase inhibitors: a speciation study
title_short Wells–Dawson phosphotungstates as mushroom tyrosinase inhibitors: a speciation study
title_sort wells–dawson phosphotungstates as mushroom tyrosinase inhibitors: a speciation study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481536/
https://www.ncbi.nlm.nih.gov/pubmed/34588468
http://dx.doi.org/10.1038/s41598-021-96491-5
work_keys_str_mv AT lamplraphael wellsdawsonphosphotungstatesasmushroomtyrosinaseinhibitorsaspeciationstudy
AT breibeckjoscha wellsdawsonphosphotungstatesasmushroomtyrosinaseinhibitorsaspeciationstudy
AT gumerovanadiiai wellsdawsonphosphotungstatesasmushroomtyrosinaseinhibitorsaspeciationstudy
AT galanskimatheasophia wellsdawsonphosphotungstatesasmushroomtyrosinaseinhibitorsaspeciationstudy
AT rompelannette wellsdawsonphosphotungstatesasmushroomtyrosinaseinhibitorsaspeciationstudy